Ritonavir
5 NDCs across 5 manufacturers|4 Generic,1 Brand
Ritonavir is used to treat acquired immunodeficiency syndrome, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Mar 1, 1996, and the first generic was approved Jan 15, 2015. FDA's Orange Book lists 5 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $7 million on Ritonavir across 51,000 claims for 6,910 beneficiaries.
Ritonavir is available as 5 NDCs from 5 manufacturers (4 generic, 1 brand), with NADAC prices from $0.61 to $8.35 per EA — the most expensive product costs about 14× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
5
4G / 1B
Manufacturers
5
competing in market
Price Spread
$0.61 – $8.35
per EA
7d Activity
avg +0.1% WoW · of 5 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
AbbVie Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Cytochrome P450 3A Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
5 manufacturers producing RITONAVIR(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
NORVIR 100 MG TABLET | $8.3489 per EA | +0.25% |
RITONAVIR 100 MG TABLET | $1.7776 per EA | — |
RITONAVIR 100 MG TABLET | $0.6066 per EA | -0.01% |
RITONAVIR 100 MG TABLET | $0.6066 per EA | -0.01% |
RITONAVIR 100 MG TABLET | $0.6066 per EA | -0.01% |
Frequently Asked Questions
What is Ritonavir used to treat?
Ritonavir is used to treat acquired immunodeficiency syndrome, per the National Library of Medicine's MED-RT classification.
When did Ritonavir become available as a generic?
FDA approved the first generic Ritonavir (ANDA) on Jan 15, 2015. The Orange Book currently lists 5 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Ritonavir?
In 2024, Medicare Part D spent $7 million on Ritonavir across 51,000 claims for 6,910 beneficiaries.
How many Ritonavir products are on the market?
The Ritonavir drug market contains 5 NDCs from 5 manufacturers — 4 generic and 1 brand product.
What is the price range for Ritonavir?
NADAC reference prices for Ritonavir range from $0.6066 to $8.3489 per EA — the most expensive product costs about 14× the cheapest.
Is generic Ritonavir cheaper than brand?
The average generic NADAC for Ritonavir is $0.8993 per EA, versus $8.3489 for brand-labeled products — brand versions average about 9.3× the generic price.
Which manufacturers make Ritonavir?
5 manufacturers list Ritonavir in NADAC. Ranked by number of NDCs, the largest are AbbVie Inc. (1), Amneal Pharmaceuticals LLC (1), Camber Pharmaceuticals Inc. (1), American Health Packaging (1), Aurobindo Pharma Limited (1).
How has the price of Ritonavir changed recently?
Over the past 7 days, 2 Ritonavir NDCs rose and 6 fell, with a market-wide average change of +0.1%.